L 703606
structure given in first source
Also Known As:
(I125)L-703606; (cis)-2-(diphenylmethyl)-N-((2-iodophenyl)methyl)-1-azabicyclo(2.2.2)octan-3-amine; 2-(diphenylmethyl)-N-((2-iodophenyl)methyl)-1-azabicyclo(2.2.2)octan-3-amine; 2-(diphenylmethyl)-N-((2-iodophenyl)methyl)-3-quinuclidinamine; L-703606; L703606
Networked: 5
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Bhatia, Madhav:
3 articles
(11/2010 - 09/2007)
|
2. | Lu, Jia:
2 articles
(11/2010 - 06/2008)
|
3. | Moochhala, Shabbir:
2 articles
(11/2010 - 06/2008)
|
4. | Chakraborty, Sanjukta:
1 article
(04/2021)
|
5. | Dhole, Saurabh:
1 article
(04/2021)
|
6. | Kumaravel, Subhashree:
1 article
(04/2021)
|
7. | Pavan, Vani:
1 article
(04/2021)
|
8. | Roy, Sukanya:
1 article
(04/2021)
|
9. | Singh, Sumeet:
1 article
(04/2021)
|
10. | He, Ji-Ye:
1 article
(11/2016)
|
Related Diseases
1. | Pneumonia (Pneumonitis)
|
2. | Burns
06/15/2008
- " More importantly, administration of L703606, a specific NK1R antagonist, 1 h before burn injury significantly disrupted the SP-NK1R signaling and reversed pulmonary inflammation and injury. " 11/15/2010
- " Notably, lung COX-2 levels were abrogated in burn-injured WT mice by L703606, PD98059, and Bay 11-7082, which are specific NK1R, MEK-1, and NF-κB antagonists, respectively. "
|
3. | Neoplasms (Cancer)
|
4. | Neoplasm Metastasis (Metastasis)
|
5. | Body Weight (Weight, Body)
|
|
Related Drugs and Biologics